Healthcare Services

Global Congenital Heart Disease (CHD) Market Set for Strong Expansion Reaching $7.27 Billion by 2030 at 8.1% CAGR

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Congenital Heart Disease (CHD) Market Projected To Become By 2030 Based On Its 2026 Valuation?

The congenital heart disease (chd) market has seen substantial growth over recent years. It is anticipated to expand from $4.85 billion in 2025 to $5.32 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.7%. Historically, this growth can be ascribed to a high incidence of structural birth defects, restricted early diagnostic abilities, the predominant use of open-heart surgery, elevated infant mortality rates, and the concentration of healthcare services in specialized tertiary hospitals.

The congenital heart disease (chd) market size is anticipated to experience substantial expansion over the forthcoming years. It is projected to reach $7.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.1%. This growth during the forecast period can be ascribed to advancements in minimally invasive cardiology, enhanced imaging and diagnostics, an increasing adult chd population, the proliferation of specialized cardiac centers, and escalating healthcare investments. Key trends anticipated for this period encompass an increase in early prenatal and neonatal screening, a surge in the adoption of catheter-based interventions, the enlargement of pediatric and adult chd care programs, higher survival rates fueling adult chd care, and comprehensive multidisciplinary long-term disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15545&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Congenital Heart Disease (CHD) Market?

The rising incidence of maternal diabetes cases is anticipated to fuel the expansion of the congenital heart disease (CHD) market. Maternal diabetes, also known as gestational diabetes mellitus (GDM), refers to diabetes that emerges during pregnancy in women who did not have the condition before conception. This condition is primarily caused by lifestyle changes, including sedentary behavior and unhealthy dietary habits, coupled with an overall increase in obesity rates among women of childbearing age. Maternal diabetes can lead to congenital heart disease (CHD) in infants because high blood sugar levels affect fetal heart development. The elevated glucose concentrations in the mother’s blood can disrupt the normal development of the baby’s heart, consequently increasing the risk of CHD. For instance, in November 2025, according to the Society For Maternal Fetal Medicine, a US-based organisation, gestational diabetes mellitus (GDM) impacts approximately 15.6% of women worldwide, with an estimated 23.3 million live births affected by hyperglycemia during pregnancy in 2024. Therefore, the growing number of maternal diabetes cases is driving the growth of the congenital heart disease (CHD) market.

What Segment Groups Are Identified Within The Congenital Heart Disease (CHD) Market?

The congenital heart disease (chd) market covered in this report is segmented –

1) By Type: Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, Other Types

2) By Diagnosis: Electrocardiogram, Chest X-ray, Echocardiogram, Transesophageal Echocardiogram, Pulse Oximetry, Exercise Stress Test, Cardiac Computed Tomography (CT) Scan Or Magnetic Resonance Imaging (MRI), Cardiac Catheterization, Other Diagnosis

3) By Treatment: Interventional Cardiology, Cardiac Surgery, Telemedicine, Medication Management, Lifestyle Modifications

4) By Age Group: Infants, Children, Adolescents, Adults

5) By Application: Hospitals And Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research And Academic Institutions

Subsegments:

1) By Heart Valve Defects: Aortic Valve Stenosis, Pulmonary Valve Stenosis, Mitral Valve Prolapse, Tricuspid Valve Defects, Valve Regurgitation

2) By Heart Wall Defects: Atrial Septal Defect (ASD), Ventricular Septal Defect (VSD), Atrioventricular Septal Defect (AVSD), Hypoplastic Left Heart Syndrome (HLHS), Tetralogy of Fallot (TOF)

3) By Blood Vessel Defects: Coarctation Of The Aorta, Patent Ductus Arteriosus (PDA), Pulmonary Artery Stenosis, Transposition Of The Great Arteries (TGA), Truncus Arteriosus

4) By Other Types: Single Ventricle Defects, Ebstein’s Anomaly, Total Anomalous Pulmonary Venous Return (TAPVR), Coronary Artery Anomalies, Pulmonary Venous Obstruction

What Trends Are Affecting The Expansion Of The Congenital Heart Disease (CHD) Market?

Leading companies within the congenital heart disease market are engaged in the development of non-surgical heart valves, aiming to enhance patient outcomes and their quality of life. These non-surgical heart valves, also known as transcatheter devices, are medical tools designed to treat heart valve conditions without requiring traditional open-heart surgery. For instance, in February 2023, Medtronic, a US-based medical technology company, brought back its Harmony Transcatheter Pulmonary Valve (TPV) System. This system provides an innovative, minimally invasive alternative to open-heart surgery for patients with congenital heart disease, particularly those with native or surgically repaired right ventricular outflow tract (RVOT) anomalies. It stands as the first FDA-approved valve specifically engineered for the right side of the heart, offering a non-surgical approach for individuals experiencing severe pulmonary valve regurgitation. The U.S. FDA initially approved the Harmony TPV System in 2021, and its reintroduction after a voluntary recall highlights Medtronic’s unwavering commitment to advancing solutions for congenital heart disease patients.

Which Companies Hold Significant Positions In The Congenital Heart Disease (CHD) Market?

Major companies operating in the congenital heart disease (chd) market are Abbott Laboratories, Medtronic, Siemens Healthineers, Philips Healthcare, Roche Diagnostics International Ltd., Boston Scientific Corp., Laboratory Corporation of America Holdings (LabCorp), Terumo Corporation, Mindray Medical International Limited, Canon Medical Systems Corporation, Masimo Corporation, Carestream Health, Schiller AG, BPL Medical Technologies, Bionet America Inc., Edwards Lifesciences Corporation, GE Healthcare, BIOTRONIK SE & Co KG, W L Gore & Associates Inc, Cook Medical, Lepu Medical Technology Co Ltd, Getinge AB, Merit Medical Systems Inc, Eurocor Tech GmbH, Braile Biomedica

Read the full congenital heart disease (chd) market report here:

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Which Regions Are Projected To Dominate The Congenital Heart Disease (CHD) Market In The Coming Years?

North America was the largest region in the congenital heart disease (CHD) market in 2025. The regions covered in the congenital heart disease (chd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Congenital Heart Disease (CHD) Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15545&type=smp

Browse Through More Reports Similar to the Global Congenital Heart Disease (CHD) Market 2026, By The Business Research Company

Congenital Heart Disease Chd Global Market Report

https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Pheochromocytoma Global Market Report

https://www.thebusinessresearchcompany.com/report/pheochromocytoma-global-market-report

Pituitary Dwarf Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/pituitary-dwarf-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795